Education
About Us
Working with TipRanks
Follow Us
Xenetic Biosciences (XBIO)
NASDAQ:XBIO
XBIO Stock Chart & Stats
$2.03
-$0.03(-0.75%)
At close: 4:00 PM EST
$2.03
-$0.03(-0.75%)
Day’s Range― - ―
52-Week Range$1.90 - $13.93
Previous CloseN/A
Volume4.73K
Average Volume (3M)1.70M
Market Cap
$5.01M
Enterprise Value$1.27M
Total Cash (Recent Filing)$4.12M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Mar 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding2,291,056
10 Day Avg. Volume5,053,508
30 Day Avg. Volume1,695,238
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)1.02
Price to Sales (P/S)2.46
P/FCF Ratio-2.18
Enterprise Value/Market Cap0.25
Enterprise Value/Revenue0.44
Enterprise Value/Gross Profit0.44
Enterprise Value/Ebitda-0.39
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsXenetic entered a clinical trial services agreement with PeriNess to advance its DNase I-based oncology platform and lead candidate, XBIO-015, in pancreatic and colorectal cancers and potentially other advanced solid tumors.
Collaborative PartnershipsXenetic's partnership with PeriNess Ltd. is pivotal in driving forward the clinical development of its DNase I platform for various cancer treatments.
Oncology AdvancementsXenetic's entry into clinical development for advanced pancreatic cancer with DNase I marks an important step in evaluating its potential in oncology.
Bears Say
Xenetic Biosciences News
XBIO FAQ
What was Xenetic Biosciences’s price range in the past 12 months?
Xenetic Biosciences lowest stock price was $1.90 and its highest was $13.93 in the past 12 months.
What is Xenetic Biosciences’s market cap?
Xenetic Biosciences’s market cap is $5.01M.
When is Xenetic Biosciences’s upcoming earnings report date?
Xenetic Biosciences’s upcoming earnings report date is Mar 25, 2026 which is in 72 days.
How were Xenetic Biosciences’s earnings last quarter?
Xenetic Biosciences released its earnings results on Nov 14, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.49 by $0.16.
Is Xenetic Biosciences overvalued?
According to Wall Street analysts Xenetic Biosciences’s price is currently Overvalued.
Does Xenetic Biosciences pay dividends?
Xenetic Biosciences does not currently pay dividends.
What is Xenetic Biosciences’s EPS estimate?
Xenetic Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xenetic Biosciences have?
Xenetic Biosciences has 2,291,056 shares outstanding.
What happened to Xenetic Biosciences’s price movement after its last earnings report?
Xenetic Biosciences reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.49. Following the earnings report the stock price went up 1.167%.
Which hedge fund is a major shareholder of Xenetic Biosciences?
Currently, no hedge funds are holding shares in XBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xenetic Biosciences
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Technical Analysis
Ownership Overview
―
Insiders
0.74% Mutual Funds
0.79% Other Institutional Investors
98.18% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---